Home » Topics » BioWorld

BioWorld
RSS

BELGIUM APPROVES BTGC GROWTH HORMONE

Feb. 3, 1992

GENELABS DEAL FOR ANTI-CANCER DRUG

Feb. 3, 1992

APPOINTMENTS AND ADVANCEMENTS

Feb. 3, 1992

SOMATIX LICENSES MYOBLAST GENE THERAPY

Feb. 3, 1992

FEDERAL BIOTECH PRIORITIES FOR 21st CENTURY

Feb. 3, 1992

JUDGE REFUSES TO SET ASIDE XOMA RULING

Feb. 3, 1992

$687 MILLION IN OFFERINGS FOR MONTH

Feb. 3, 1992

FDA PANEL TURNS DOWN U.S. BIO'S ETHYOL

Feb. 3, 1992

GENSIA TO EVALUATE EYE TREATMENT

Jan. 31, 1992

POSITIVE RESULTS FROM AIDS VACCINE TRIAL

Jan. 31, 1992

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...